YESCARTA

YESCARTA (axicabtagene ciloleucel) Patient Guide: How to Get YESCARTA at Low or No Cost

YESCARTA is a specialized CAR T-cell therapy from Kite Pharma Inc. for certain types of relapsed or refractory non-Hodgkin lymphoma, but Kite does not offer a direct manufacturer patient assistance program (PAP). Instead, they refer patients to independent nonprofit organizations for financial help.[1][2][4]

About YESCARTA

YESCARTA (axicabtagene ciloleucel) is a groundbreaking prescription medicine—a CD19-directed genetically modified autologous T cell immunotherapy. It uses your own T cells, modified in a lab to fight cancer, and is FDA-approved for:

• Adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months.[2][3]
• Relapsed or refractory large B-cell lymphoma after two or more lines of therapy, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL from follicular lymphoma.[2]
• Recently updated for relapsed/refractory primary central nervous system lymphoma (PCNSL).[3]
• Follicular lymphoma after at least two failed treatments.[1][5]

This one-time infusion therapy can offer durable responses and long-term survival, with real-world data showing benefits even in outpatient settings.[6][7] However, it's only available at Authorized Treatment Centers (ATCs) enrolled in the YESCARTA and TECARTUS REMS program due to risks like Cytokine Release Syndrome (CRS) and neurologic toxicities. Facilities must have tocilizumab on hand for emergencies.[2][6][7]

Important safety note: Watch for fever, chills, confusion, fast heartbeat, or breathing issues post-infusion. Carry your YESCARTA Patient Wallet Card and seek immediate care if symptoms arise. Tell your doctor about all health conditions and medications before treatment.[1][2]

Who Qualifies for Assistance?

Kite Pharma does not run its own PAP. No specific income thresholds, insurance rules, or eligibility criteria are set by Kite—they direct patients to independent third-party nonprofit patient assistance programs. Eligibility varies by organization, often based on financial need, lack of insurance coverage, or high out-of-pocket costs.[1][2][4][5]

Contact Kite Konnect at 1-844-454-KITE (5483), Monday–Friday, 5 AM–6 PM PT, for referrals to these nonprofits, ATC locations, transportation/lodging help, and reimbursement support.[2][4][9]

Income Eligibility Breakdown

Since there's no Kite PAP, here's a general guide to common nonprofit criteria (always verify with the specific program):

Notes: FPL = Federal Poverty Level. Nonprofits may cover uninsured/underinsured patients regardless of income if costs are unaffordable. Medicare/Medicaid patients might qualify for copay aid via other channels.[2][10]

Insurance Requirements

Assistance often targets:

• Uninsured or underinsured patients.
• Those with commercial insurance facing high copays.
• Medicare/Medicaid enrollees (program availability varies; some copay cards listed but may be inactive).[10]

Kite Konnect provides payer coverage maps and reimbursement support. YESCARTA requires prior authorization; your doctor and ATC handle this.[2][4]

Step-by-Step Application Process

1. Consult your doctor: Confirm YESCARTA is right for you and get a prescription. Discuss ATC options.[4]
2. Call Kite Konnect: Dial 1-844-454-KITE (5483). Share your situation—they'll refer you to nonprofits, explain logistics, and connect to an ATC.[2][4][9]
3. Contact referred nonprofits: Apply directly (e.g., via their websites or phone). Provide proof of income, prescription, and insurance details.
4. Gather documents: Typically, tax returns, pay stubs, insurance cards (see FAQ for details).
5. Submit application: Online, mail, or fax—nonprofits guide you.
6. Follow up: Track status with Kite Konnect or the nonprofit.

Your ATC coordinates infusion once approved.[1][9]

Timeline and Delivery

• Kite Konnect response: Immediate referrals.[2]
• Nonprofit approval: 1-4 weeks, depending on program (call for estimates).
• Manufacturing/Infusion: Personalized cells take 3-4 weeks to produce after leukapheresis (cell collection).[1]
• Delivery: Infused at ATC only; monitored 7-14 days for CRS.[2][7]

Total from referral to treatment: 4-8 weeks or more.

Alternatives if Denied

• Appeal the denial with more docs or doctor letter.
• Other nonprofits: PAN Foundation, Patient Access Network, or CancerCare (ask Kite Konnect).[1]
• Hospital charity care or state programs.
• Clinical trials via ClinicalTrials.gov.
• Financial counseling at your cancer center.
• Copay cards if commercially insured (check availability).[10]

Biosimilar Alternatives

No biosimilars exist for YESCARTA—it's a unique autologous CAR T therapy. Other CAR Ts like Tecartus or Breyanzi may be options; discuss with your doctor.[2]

Disclaimer

This guide is for informational purposes only and not medical or financial advice. Assistance programs change; eligibility is not guaranteed. Consult healthcare providers, Kite Konnect, and nonprofits directly. Kite makes no guarantees about third-party programs.[1][2][4] Word count: 1028.